Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eIF3b siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
eIF3b siRNA is a small interfering RNA (siRNA) research compound designed to silence the expression of the eukaryotic translation initiation factor 3 subunit b (eIF3b). As a key scaffolding component of the eIF3 complex, eIF3b is essential for the initiation of protein translation and has been found to be overexpressed in numerous cancers, including bladder, prostate, and gastric malignancies. By utilizing the RNA interference (RNAi) pathway, eIF3b siRNA mediates the degradation of EIF3B mRNA, leading to reduced protein levels. Preclinical studies have demonstrated that this knockdown inhibits cell proliferation, induces G1 cell cycle arrest, and suppresses migration and metastasis by modulating downstream signaling pathways such as FAK and Akt. It is widely used as a laboratory tool to study the role of translation initiation in disease progression.
- Other names
- siRNA targeting eIF3bEIF3B siRNAEIF-3B siRNAEIF 3B siRNAeIF3b-siRNAeIF-3b-siRNAeIF 3b-siRNA
02
Targets
HPRT1 (Hypoxanthine-guanine phosphoribosyltransferase)
Beyond the preview
Go deeper on eIF3b siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eIF3b siRNA.